{"success":true,"data":{"pressRelease":{"id":"128770","rtpr_id":"nBw4wdh5Xa","ticker":"MTLS","exchange":"","all_tickers":["MTLS"],"title":"Materialise Reports Second Quarter and Half-Year 2026 Results","author":"Business Wire","published_at":"2026-08-27T05:00:00.145Z","article_body":"Materialise Reports Second Quarter and Half-Year 2026 Results\n\nRegulated information(1)\n\nMaterialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed\nmedical devices and software, and a pioneer in additive manufacturing software\nand services, today announced its financial results for the second quarter and\nthe six months ended June 30, 2026.\n\nHighlights – Second Quarter 2026\n\n\n * Total revenue increased by 8.1% to 70,073 kEUR for the second quarter of 2026\ncompared to 64,831 kEUR for the corresponding 2025 period.\n\n * Adjusted EBITDA increased by 15.7% to 9,593 kEUR for the second quarter of\n2026 compared to 8,288 kEUR for the second quarter of 2025.\n\n * Adjusted EBIT increased by 26.9% to 3,880 kEUR for the second quarter of 2026\nfrom 3,058 kEUR for the second quarter of 2025.\n\n * Net profit for the second quarter of 2026 amounted to 3,331 kEUR, or 0.06 EUR\nper diluted share, compared to net profit of 199 kEUR, or 0.00 EUR per diluted\nshare, for the corresponding 2025 period.\n\n * The net cash position at quarter end was 74,214 kEUR, 1,388 kEUR higher\ncompared to the net cash position as of March 31, 2026 while 2,903 kEUR was\ninvested in share buybacks, underscoring continued strong operational cash\ngeneration.\n\nHighlights – Half-Year 2026\n\n\n * Driven by a strong 9.6% growth in our Materialise Medical segment, total\nrevenue increased by 3.9% to 136,349 kEUR for the first half of 2026 compared\nto 131,210 kEUR for the first half of 2025.\n\n * Gross profit as a percentage of revenue for the first half of 2026 was 57.0%,\ncompared to 56.8% for the first half of 2025.\n\n * Adjusted EBITDA increased by 22.2% to 17,642 kEUR for the first half of 2026\ncompared to 14,434 kEUR for the first half of 2025. Adjusted EBIT increased by\n71.4% to 6,351 kEUR for the first half of 2026 from 3,703 kEUR for the first\nhalf of 2025.\n\n * Net profit for the first half of 2026 amounted to 5,152 kEUR, or 0.09 EUR per\ndiluted share, compared to a net loss of (337) kEUR, or (0.01) EUR per diluted\nshare, for the first half of 2025.\n\n * Total cash reserves amounted to 133,735 kEUR at the end of the first half of\n2026. The net cash position increased by 3,409 kEUR during the first half of\n2026, while 5,212 kEUR was invested in share buybacks.\n\nCEO Brigitte de Vet-Veithen commented, “In the second quarter of 2026,\nMaterialise delivered strong financial results with consolidated revenue\nexceeding EUR 70 million, up 8% year over year. Double-digit revenue growth in\nour Materialise Medical segment was complemented by renewed growth in our\nManufacturing segment driven by strong performance in our aerospace &\ndefense focus markets. Combined with disciplined cost management and focused\nexecution, this revenue growth translated into a significant improvement in\noperational and bottomline profitability. Our net cash position further\nstrengthened supported by consistent operating cash flow while we continued\nthe execution of our share buyback program.\n\nWe also made meaningful progress against our strategic priorities during the\nquarter. Our Materialise Software segment launched its new CO-AM offerings, we\ncompleted the previously announced divestitures of our RapidFit and Eyewear\nbusiness lines, and we invested in Replasia to further expand our personalized\nhip care portfolio. These actions reflect our commitment to sharpening our\nfocus, strengthening our leadership in high-value applications, and building\nthe foundation for sustainable long-term growth. With a strong balance sheet,\nMaterialise is well positioned to capture further opportunities ahead and to\ncreate lasting value for customers, patients, partners, and shareholders.”\n __________________________ \n (1 )The enclosed information constitutes regulated information as defined in \n the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers \n of financial instruments which have been admitted for trading on a regulated \n market. \n\n\nSecond quarter 2026 Results\n\nTotal revenue for the second quarter of 2026 increased by 8.1% to 70,073 kEUR\nfrom 64,831 kEUR for the second quarter of 2025. Adjusted EBIT increased by\n26.9% to 3,880 kEUR for the second quarter of 2026 compared to 3,058 kEUR for\nthe 2025 period. The Adjusted EBIT margin (Adjusted EBIT divided by total\nrevenue) for the second quarter of 2026 was 5.5%, compared to 4.7% for the\nsecond quarter of 2025. Adjusted EBITDA for the second quarter of 2026\nincreased by 15.7% to 9,593 kEUR compared to 8,288 kEUR for the 2025 period.\n\nRevenue from our Materialise Medical segment increased 12.2% to 36,873 kEUR\nfor the second quarter of 2026 compared to 32,850 kEUR for the same period in\n2025. Segment Adjusted EBITDA increased 7.7% to 11,553 kEUR for the second\nquarter of 2026 compared to 10,728 kEUR, while the segment Adjusted EBITDA\nmargin was 31.3% compared to 32.7% for the second quarter of 2025.\n\nRevenue from our Materialise Software segment decreased 2.7% to 9,601 kEUR for\nthe second quarter of 2026 from 9,872 kEUR for the same quarter last year.\nSegment Adjusted EBITDA decreased to 981 kEUR from 1,373 kEUR, while the\nsegment Adjusted EBITDA margin was 10.2% compared to 13.9% for the prior-year\nperiod.\n\nRevenue from our Materialise Manufacturing segment increased 6.7% to 23,597\nkEUR for the second quarter of 2026 from 22,109 kEUR for the second quarter of\n2025. Segment Adjusted EBITDA improved to (285) kEUR compared to (807) kEUR\nfor the same period in 2025, while the segment Adjusted EBITDA margin was\n(1.2)% compared to (3.6)% for the second quarter of 2025.\n\nGross profit increased 5.3% to 39,776 kEUR for the second quarter of 2026\ncompared to 37,778 kEUR for the same period last year, while gross profit as a\npercentage of revenue ended at 56.8% compared to 58.3% for the second quarter\nof 2025.\n\nResearch and development (“R&D”), sales and marketing (“S&M”),\nand general and administrative (“G&A”) expenses increased, in the\naggregate, by 3.9% to 37,758 kEUR for the second quarter of 2026 from 36,334\nkEUR for the second quarter of 2025.\n\nNet other operating income was 766 kEUR compared to 1,286 kEUR for the second\nquarter of 2025. Net operating income in the second quarter of 2026 includes\nnon-recurring charges of 689 kEUR from the impairment of tangible and\nintangible assets related to the transfer of the Eyewear assets.\n\nOperating result remained fairly stable at 2,785 kEUR compared to 2,730 kEUR\nfor the second quarter of 2025, while net financial result was 242 kEUR,\ncompared to (3,052) kEUR for the second quarter of 2025. The latter being\nsignificantly impacted by unfavorable foreign exchange results.\n\nThe second quarter of 2026 contained net tax benefits of 304 kEUR, compared to\nnet tax benefits of 521 kEUR in the second quarter of 2025.\n\nAs a result of the above, net profit for the second quarter of 2026 increased\nsharply to 3,331 kEUR, compared to 199 kEUR for the same period in 2025.\n\nCash flow from operating activities for the second quarter of 2026 amounted to\n8,146 kEUR compared to (27) kEUR for the same period in 2025. Total cash used\nfor capital expenditures for the second quarter of 2026 amounted to 1,975 kEUR\nand free cash flow after operating and investing activities was 5,625 kEUR.\n\nHalf-Year 2026 Results\n\nTotal revenue for the first half of 2026 increased by 3.9% to 136,349 kEUR,\ncompared to 131,210 kEUR for the same period in 2025. Adjusted EBIT for the\nfirst half of 2026 increased by 71.4% to 6,351 kEUR, up from 3,703 kEUR for\nthe corresponding period in 2025. The Adjusted EBIT margin (Adjusted EBIT\ndivided by total revenue) for the first half of 2026 increased to 4.7%,\ncompared to 2.8% for the same period in 2025. Adjusted EBITDA for the first\nhalf of 2026 increased by 22.2% to 17,642 kEUR, compared to 14,434 kEUR for\nthe same period in 2025.\n\nRevenue from our Materialise Medical segment increased by 9.6% to 70,039 kEUR\nfor the first half of 2026, compared to 63,928 kEUR for the same period in\n2025. The segment’s Adjusted EBITDA increased by 5.1% to 20,787 kEUR from\n19,775 kEUR. The segment’s Adjusted EBITDA margin ended at 29.7% in the\nfirst half of 2026 compared to 30.9% for the first half of 2025.\n\nRevenue from our Materialise Software segment decreased 2.1% to 19,242 kEUR\nfor the first half of 2026 compared to 19,647 kEUR for the same period in\n2025. The segment’s Adjusted EBITDA increased by 6.7% to 2,103 kEUR from\n1,971 kEUR. The segment’s Adjusted EBITDA margin improved to 10.9% in the\nfirst half of 2026, compared to 10.0% in the first half of 2025.\n\nRevenue from our Materialise Manufacturing segment decreased 1.2% to 47,067\nkEUR for the first half of 2026 from 47,635 kEUR for the first half of 2025.\nThe segment’s Adjusted EBITDA improved to (4) kEUR compared to (1,185) kEUR.\nThe segment’s Adjusted EBITDA margin was (0.0)% in the first half of 2026,\ncompared to (2.5)% in the first half of 2025.\n\nConsolidated gross profit increased 4.3% to 77,670 kEUR from 74,502 kEUR in\nlast year’s first half. Gross profit as a percentage of revenue increased to\n57.0%, compared to 56.8% in the first half of 2025.\n\nResearch and development (“R&D”) expenses increased by 7.4% to 24,203\nkEUR in the first half of 2026 reflecting higher investments in our\nMaterialise Medical and Software segments. Other operational expenses,\nincluding sales and marketing (\"S&M\") and general and administrative\n(\"G&A\") expenses, remained stable in aggregate at 50,268 kEUR for the\nfirst half of 2026, compared to 50,311 kEUR for the first half of 2025.\n\nNet other operating income was 1,676 kEUR compared to 1,646 kEUR for the first\nhalf of 2025.\n\nOperating result increased to 4,875 kEUR for the first half of 2026 compared\nto 3,303 kEUR in the same period of the prior year.\n\nNet financial result amounted to 634 kEUR, compared to (3,927) kEUR for the\nfirst half of 2025.\n\nIncome taxes amounted to (358) kEUR compared to 287 kEUR for the first half of\n2025.\n\nAs a result, net profit amounted to 5,152 kEUR for the first half of 2026\ncompared to a net loss of (337) kEUR in the first half of 2025.\n\nCash flow from operating activities for the first half of 2026 increased to\n15,060 kEUR compared to 9,686 kEUR for the first half of 2025. Total capital\nexpenditures for the first half of 2026 amounted to 3,445 kEUR compared to\n6,561 kEUR for the first half of 2025. Free cash flow, after operating and\ninvesting activities, for the first half of 2026 amounted to 11,368 kEUR.\n\nAt June 30, 2026, we held cash and cash equivalents of 133,735 kEUR compared\nto 133,918 kEUR at December 31, 2025. Gross debt decreased to 59,521 kEUR,\ncompared to 63,113 kEUR at December 31, 2025. As a result, our net cash\nposition increased by 3,409 kEUR to 74,214 kEUR compared to 70,805 kEUR as of\nDecember 31, 2025. At the end of the second quarter of 2026 Materialise had\nbought back 1,070,797 own shares for a total amount (excluding transaction\ncost) of 5,212 kEUR (6,091 kUSD) under its previously announced share buy-back\nprogram.\n\nNet shareholders' equity at June 30, 2026 increased to 256,268 kEUR compared\nto 255,482 kEUR at December 31, 2025.\n\nOn August 27, 2026, Materialise released its 2026 Half-Year Report providing\nfurther insights in its operational and financial performance over the first\nhalf of 2026. This report is now also available on our Investor Relations\nwebsite under the reports\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.materialise.com%2Ffinancials%2Freports&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=reports&index=1&md5=5f2e54a86fb7a5c45b4d8ed3d96f25e9)\nsection. The timing of our second quarter financial results update was\nintentionally aligned with the public release of the 2026 Half-Year report.\n\n2026 Guidance\n\nMrs. de Vet-Veithen concluded,“Our solid first-half year performance\nreinforces our confidence in delivering on the financial targets we set for\n2026. The strategic actions we are taking to sharpen our portfolio and the\ntargeted investments we are making across our three segments are enhancing\noperational performance and positioning Materialise for profitable growth.\nAccordingly, we are reaffirming our full-year 2026 revenue guidance of 273,000\nto 283,000 kEUR, fully absorbing the unfavorable revenue impact of the\nRapidFit and Eyewear divestments. At the same time we are increasing our\nfull-year Adjusted EBIT guidance to a range of 12,000 to 14,000 kEUR from a\npreviously communicated range of 10,000 to 12,000 kEUR, reflecting the\nstrength of our execution and our continued discipline in managing costs and\ncapital.”\n\nNon-IFRS Measures\n\nMaterialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as\nsupplemental financial measures of its financial performance, including for\npurposes of monitoring compliance with financial covenants, supporting\ndiscussions with financing institutions, and meeting reporting requirements to\nour banks. EBIT is calculated as net profit plus income taxes, financial\nexpenses (less financial income) and shares of profit or loss in a joint\nventure. EBITDA is calculated as net profit plus income taxes, financial\nexpenses (less financial income), shares of profit or loss in a joint venture\nand depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are\ndetermined by adding to EBIT and EBITDA, respectively (i) share-based\ncompensation expenses, (ii) acquisition expenses related to business\ncombinations or divestiture-related expenses, (iii) impairments and\nrevaluation of fair value due to business combinations and (iv) costs incurred\nin relation to corporate initiatives, restructurings or reorganizations that\nare of a non-recurring nature. Management believes these non-IFRS measures to\nbe important measures as they exclude the effects of items which primarily\nreflect the impact of financing decisions and, in the case of EBITDA and\nAdjusted EBITDA, long term investment, rather than the performance of the\ncompany’s day-to-day operations. The company also uses segment Adjusted\nEBITDA and segment Adjusted EBITDA margin to evaluate the performance of its\nthree business segments. As compared to net profit, these measures are limited\nin that they do not reflect the cash requirements necessary to service\ninterest or principal payments on the company’s indebtedness and, in the\ncase of EBITDA and Adjusted EBITDA, these measures are further limited in that\nthey do not reflect the periodic costs of certain capitalized tangible and\nintangible assets used in generating revenues in the company’s business, or\nthe changes associated with impairments. Management evaluates such items\nthrough other financial measures such as financial expenses, capital\nexpenditures and cash flow provided by operating activities. The company\nbelieves that these measurements are useful to measure a company’s ability\nto grow or as a valuation measurement. The company’s calculation of EBIT,\nEBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly\ntitled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and\nAdjusted EBITDA should not be considered as alternatives to net profit or any\nother performance measure derived in accordance with IFRS. The company’s\npresentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be\nconstrued to imply that its future results will be unaffected by unusual or\nnon-recurring items.\n\nExchange Rate\n\nThis document contains translations of certain euro amounts into U.S. dollars\nat specified rates solely for the convenience of readers. Unless otherwise\nnoted, all translations from euros to U.S. dollars in this document were made\nat a rate of EUR 1.00 to USD 1.1394, the reference rate of the European\nCentral Bank on June 30, 2026.\n\nConference Call and Webcast\n\nMaterialise will hold a conference call and simultaneous webcast to discuss\nits second quarter and half-year financial results of 2026 on Thursday, August\n27, 2026, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will\ninclude Brigitte de Vet-Veithen, Chief Executive Officer and Koen Berges,\nChief Financial Officer. A question-and-answer session will follow\nmanagement’s remarks.\n\nTo access the call by phone, please click the link below at least 15 minutes\nprior to the scheduled start time and you will be provided with dial-in\ndetails. Participants can choose to dial in or receive a call to connect to\nMaterialise’s conference call.\n\n\n * https://register-conf.media-server.com/register/BI1b662511962140febfa1a767c86a06ee\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI1b662511962140febfa1a767c86a06ee&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI1b662511962140febfa1a767c86a06ee&index=2&md5=114a38bf5b1cbea16acac6085c09eefc)\n\nThe conference call will also be broadcast live over the Internet with an\naccompanying slide presentation, which can be accessed on the company’s\nwebsite at http://investors.materialise.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestors.materialise.com&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=http%3A%2F%2Finvestors.materialise.com&index=3&md5=d7583eab6c255bb3ea65d2bb3af1c9c9)\n. The webcast of the conference call will be archived on the company's website\nfor one year.\n\nAbout Materialise\n\nMaterialise NV incorporates more than three decades of 3D printing experience\ninto a range of software solutions and 3D printing services that empower\nsustainable 3D printing applications. Our open, secure, and innovative\nend-to-end solutions enable flexible industrial manufacturing and mass\npersonalization in various industries — including healthcare, automotive,\naerospace, art and design, wearables, and consumer goods. Headquartered in\nBelgium and with branches worldwide, Materialise NV combines the largest group\nof software developers in the industry with one of the world's largest and\nmost complete 3D printing facilities. For additional information, please\nvisit: www.materialise.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.materialise.com&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=www.materialise.com&index=4&md5=e5ffee95159e11086b6d6f3317bd5c8c)\n.\n\nCautionary Statement on Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, regarding, among other things,\nour intentions, beliefs, assumptions, projections, outlook, analyses or\ncurrent expectations, plans, objectives, strategies and prospects, both\nfinancial and business, including statements concerning, among other things,\nour estimates for the current fiscal year’s revenue and Adjusted EBIT, our\nresults of operations, cash needs, capital expenditures, expenses, financial\ncondition, liquidity, prospects, divestitures, growth and strategies\n(including how our business, results of operations and financial condition\ncould be impacted by the current armed geopolitical conflicts around the world\nand governmental responses thereto, inflation, increased labor, energy and\nmaterials costs), policy changes resulting from the U.S. presidential\nadministration, changes in tariffs and trade restrictions, and the trends and\ncompetition that may affect the markets, industry or us. Such statements are\nsubject to known and unknown uncertainties and risks. When used in this press\nrelease, the words “estimate,” “expect,” “anticipate,”\n“project,” “plan,” “intend,” “believe,” “forecast,”\n“will,” “may,” “could,” “might,” “aim,” “should,” and\nvariations of such words or similar expressions are intended to identify\nforward-looking statements. These forward-looking statements are based upon\nthe expectations of management under current assumptions at the time of this\npress release. These expectations, beliefs and projections are expressed in\ngood faith and the company believes there is a reasonable basis for them.\nHowever, the company cannot offer any assurance that our expectations, beliefs\nand projections will actually be achieved. By their nature, forward-looking\nstatements involve risks and uncertainties because they relate to events,\ncompetitive dynamics and industry change, and depend on economic circumstances\nthat may or may not occur in the future or may occur on longer or shorter\ntimelines than anticipated. We caution you that forward-looking statements are\nnot guarantees of future performance and involve known and unknown risks,\nuncertainties and other factors that are in some cases beyond our control. All\nof the forward-looking statements are subject to risks and uncertainties that\nmay cause the company's actual results to differ materially from our\nexpectations, including risk factors described in the company's most recent\nannual report on Form 20-F filed with the U.S. Securities and Exchange\nCommission. There are a number of risks and uncertainties that could cause the\ncompany's actual results to differ materially from the forward-looking\nstatements contained in this press release.\n\nThe company is providing this information as of the date of this press release\nand does not undertake any obligation to update any forward-looking statements\ncontained in this press release as a result of new information, future events\nor otherwise, unless it has obligations under the federal securities laws to\nupdate and disclose material developments related to previously disclosed\ninformation.\n Consolidated income statements (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In '000 2026   2026   2025   2026   2025   \n U.S.$ € € € € \n Revenue 79,841   70,073   64,831   136,349   131,210   \n Cost of Sales (34,520 ) (30,297 ) (27,053 ) (58,679 ) (56,708 ) \n Gross Profit 45,321   39,776   37,778   77,670   74,502   \n Gross profit as % of revenue 56.8 % 56.8 % 58.3 % 57.0 % 56.8 % \n   \n Research and development expenses (14,029 ) (12,312 ) (11,120 ) (24,203 ) (22,534 ) \n Sales and marketing expenses (17,329 ) (15,209 ) (15,471 ) (30,644 ) (30,542 ) \n General and administrative expenses (11,663 ) (10,236 ) (9,744 ) (19,623 ) (19,769 ) \n Net other operating income/(expense) 873   766   1,286   1,676   1,646   \n Operating profit (loss) 3,173   2,785   2,730   4,875   3,303   \n   \n Financial expenses (993 ) (871 ) (4,039 ) (1,571 ) (6,811 ) \n Financial income 1,268   1,113   987   2,205   2,884   \n Profit (loss) before taxes 3,448   3,027   (322 ) 5,510   (624 ) \n   \n Income tax benefit/(expense) 347   304   521   (358 ) 287   \n Net profit (loss) for the period 3,795   3,331   199   5,152   (337 ) \n Net profit (loss) attributable to: \n The owners of the parent 3,795   3,331   199   5,152   (336 ) \n Non-controlling interest -   0   -   0   (2 ) \n   \n Earning per share attributable to owners of the parent \n Basic 0.07   0.06   0.00   0.09   (0.01 ) \n Diluted 0.07   0.06   0.00   0.09   (0.01 ) \n   \n Weighted average basic shares outstanding 58,310   58,310   59,067   58,586   59,067   \n Weighted average diluted shares outstanding 58,329   58,329   59,067   58,592   59,067   \n\n Consolidated statements of comprehensive income (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2026   2025 2026   2025   \n U.S.$ € € € € \n Net profit (loss) for the period 3,795   3,331   199 5,152   (337 ) \n Other comprehensive income/(loss) \n Items that are or may be reclassified subsequently to profit or loss \n Exchange difference on translation of foreign operations 91   80   624 257   1,129   \n Exchange differences resulting from net investment in foreign operations 182   160   - 537   -   \n Other comprehensive income/(loss), net of taxes 273   240   624 794   1,129   \n Total comprehensive income/(loss), net of taxes 4,069   3,571   823 5,946   792   \n Total comprehensive income/(loss) attributable to: \n The owners of the parent 4,071   3,573   817 5,951   785   \n Non-controlling interests (2 ) (2 ) 6 (5 ) 7   \n\n Consolidated statement of financial position (Unaudited) \n   \n As of As of \n June 30, December 31, \n In 000€ 2026 2025 \n Assets \n Non-current assets \n Goodwill 43,205 43,161 \n Intangible assets 23,281 25,639 \n Property, plant & equipment 109,776 112,854 \n Right-of-Use assets 5,873 5,429 \n Deferred tax assets 4,158 3,971 \n Investments in convertible loans 404 - \n Investments in non-listed equity instruments 8 - \n Other non-current assets 9,739 5,983 \n Total non-current assets 196,443 197,038 \n Current assets \n Inventories 16,846 14,904 \n Trade receivables 56,173 54,938 \n Other current assets 14,468 15,533 \n Cash and cash equivalents 133,735 133,918 \n Assets held for sale 0 4,314 \n Total current assets 221,221 223,607 \n Total assets 417,665 420,646 \n\n As of As of \n June 30, December 31, \n In 000€ 2026   2025   \n Equity and liabilities \n Equity \n Share capital 4,487   4,487   \n Share premium 203,895   203,895   \n Treasury shares (5,230 ) -   \n Retained earnings and other reserves 53,202   47,180   \n Equity attributable to the owners of the parent 256,354   255,562   \n Non-controlling interest (86 ) (80 ) \n Total equity 256,268   255,482   \n Non-current liabilities \n Loans & borrowings 46,745   49,726   \n Lease liabilities 3,526   3,063   \n Deferred tax liabilities 2,467   2,660   \n Deferred income 16,286   17,344   \n Other non-current liabilities 417   486   \n Total non-current liabilities 69,441   73,280   \n Current liabilities \n Loans & borrowings 6,775   7,759   \n Lease liabilities 2,475   2,565   \n Trade payables 19,382   20,125   \n Tax payables 934   748   \n Deferred income 46,267   43,523   \n Other current liabilities 16,122   16,362   \n Liabilities held for sale 0   802   \n Total current liabilities 91,955   91,884   \n Total equity and liabilities 417,665   420,646   \n\n Consolidated statement of cash flows (Unaudited) \n   \n for the six months ended \n June 30, \n In 000€ 2026   2025   \n Operating activities \n Net (loss) profit for the period 5,152   (337 ) \n Non-cash and operational adjustments \n Depreciation of property plant & equipment 8,097   7,448   \n Amortization of intangible assets 3,965   3,210   \n Share-based payment expense 115   117   \n Loss (gain) on disposal of intangible assets and property, plant & equipment (331 ) (21 ) \n Government grants (239 ) (101 ) \n Movement in provisions (49 ) (366 ) \n Movement reserve for bad debt and slow moving inventory 449   271   \n Financial income (2,225 ) (2,876 ) \n Financial expense 1,598   6,770   \n Impact of foreign currencies (59 ) (70 ) \n Income taxes and deferred taxes 359   (295 ) \n Working capital adjustments and income tax (paid)/received \n Decrease (increase) in trade receivables and other receivables (210 ) 2,093   \n Decrease (increase) in inventories and contracts in progress (2,246 ) (500 ) \n Increase in trade payables and other payables (807 ) (6,278 ) \n Income tax (paid)/received 184   (679 ) \n Interest received 1,308   1,300   \n Net cash flow from operating activities 15,060   9,686   \n\n for the six months ended \n June 30, \n In 000€ 2026   2025   \n Investing activities \n Purchase of property, plant & equipment (2,792 ) (5,617 ) \n Purchase of intangible assets (654 ) (944 ) \n Proceeds from the sale of property, plant & equipment & intangible assets 409   233   \n Cash transferred out upon divestment (488 ) -   \n Investments in associates and joint ventures (8 ) -   \n Convertible loan to third party (400 ) -   \n Capital government grants received 240   2,640   \n Net cash flow used in investing activities (3,692 ) (3,688 ) \n Financing activities \n Proceeds from loans & borrowings -   20,000   \n Repayment of loans & borrowings (3,951 ) (6,860 ) \n Repayment of leases (1,917 ) (1,544 ) \n Interest paid (978 ) (621 ) \n Other financial income (expense), net 18   (1,300 ) \n Repurchase of treasury shares (5,230 ) -   \n Net cash flow from (used in) financing activities (12,058 ) 9,676   \n Net increase/(decrease) of cash & cash equivalents (690 ) 15,673   \n Cash & Cash equivalents at the beginning of the year 133,918   102,304   \n Exchange rate differences on cash & cash equivalents 507   (913 ) \n Cash & cash equivalents at end of the period 133,735   117,064   \n\n Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n Depreciation and amortization 5,712   5,230   11,291   10,731   \n EBITDA 8,497   7,960   16,167   14,034   \n Share-based compensation expense (1) 59   45   115   117   \n Restructuring and corporate initiatives (2) 178   283   435   283   \n Impairments (3) 689   -   756   -   \n Divestitures-related expenses (4) 169   -   169   -   \n Adjusted EBITDA 9,593   8,288   17,642   14,434   \n\n (1) Share-based compensation expense represents the cost of equity-settled and \n share-based payments to employees. \n (2) Non-recurring costs related to corporate initiatives, restructurings or \n reorganizations. \n (3) Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (4) Divestitures-related expenses represent fees and costs in connection with the \n divestitures of RapidFit and Eyewear. \n\n Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n EBIT 2,785   2,730   4,876   3,303   \n Share-based compensation expense (1) 59   45   115   117   \n Restructuring and corporate initiatives (2) 178   283   435   283   \n Impairments (3) 689   -   756   -   \n Divestitures-related expenses (4) 169   -   169   -   \n Adjusted EBIT 3,880   3,058   6,351   3,703   \n\n (1)   Share-based compensation expense represents the cost of equity-settled and \n share-based payments to employees. \n (2)   Non-recurring costs related to corporate initiatives, restructurings or \n reorganizations. \n (3)   Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (4)   Divestitures-related expenses represent fees and costs in connection with the \n divestitures of RapidFit and Eyewear. \n\n Segment P&L (Unaudited) \n   \n In 000€ Materialise Materialise Materialise Total Unallocated (1) Consolidated \n Medical Software Manufacturing segments \n For the three months ended June 30, 2026 \n Revenues 36,873   9,601   23,597   70,071   2   70,073   \n Segment (adj) EBITDA 11,553   981   (285 ) 12,248   (2,656 ) 9,593   \n Segment (adj) EBITDA % 31.3 % 10.2 % -1.2 % 17.5 % 13.7 % \n For the three months ended June 30, 2025 \n Revenues 32,850   9,872   22,109   64,831   (0 ) 64,831   \n Segment (adj) EBITDA 10,728   1,373   (807 ) 11,294   (3,005 ) 8,288   \n Segment (adj) EBITDA % 32.7 % 13.9 % -3.6 % 17.4 % 12.8 % \n   \n In 000€ Materialise Materialise Materialise Total Unallocated (1) Consolidated \n Medical Software Manufacturing segments \n For the six months ended June 30, 2026 \n Revenues 70,039   19,242   47,067   136,347   2   136,349   \n Segment (adj) EBITDA 20,787   2,103   (4 ) 22,886   (5,245 ) 17,642   \n Segment (adj) EBITDA % 29.7 % 10.9 % 0.0 % 16.8 % 12.9 % \n For the six months ended June 30, 2025 \n Revenues 63,928   19,647   47,635   131,210   (0 ) 131,210   \n Segment (adj) EBITDA 19,775   1,971   (1,185 ) 20,561   (6,127 ) 14,434   \n Segment (adj) EBITDA % 30.9 % 10.0 % -2.5 % 15.7 % 11.0 % \n\n (1)    Unallocated segment adjusted EBITDA consists of corporate research and \n development and corporate other operating income (expense), and the added \n share-based compensation expenses, acquisition expenses related to business \n combinations or divestiture-related expenses, impairments and revaluation of \n fair value of business combinations and non-recurring costs related to \n corporate initiatives, restructurings and reorganizations that are included in \n Adjusted EBITDA and that are not allocated to the reporting segments . \n\n Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n Operating (loss) profit 2,785   2,730   4,876   3,303   \n Depreciation and amortization 5,712   5,230   11,291   10,731   \n Corporate research and development 935   1,070   1,813   2,100   \n Corporate headquarter costs 3,219   2,895   6,215   5,747   \n Other operating income (expense) (1,151 ) (810 ) (2,125 ) (1,498 ) \n Impairments (1) 689   -   756   -   \n Segment restructuring and reorganization (2) 59   178   59   178   \n Segment adjusted EBITDA 12,248   11,294   22,886   20,561   \n\n (1)    Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (2)    Costs related to restructuring activities and organizational changes within \n specific reported business segments, including personnel‑related and other \n associated expenses. \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260826250614/en/\n(https://www.businesswire.com/news/home/20260826250614/en/)\n\nInvestor Relations Contact\n\nJody Burfening\n\nAlliance Advisors Investor Relations\n\n+1-212-838-3777\n\nMaterialiseIR@allianceadvisors.com (mailto:MaterialiseIR@allianceadvisors.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw4wdh5Xa","title":"Materialise Reports Second Quarter and Half-Year 2026 Results","author":"Business Wire","ticker":"MTLS","created":"2026-08-27T05:00:00.145Z","tickers":["MTLS"],"exchange":"","article_body":"Materialise Reports Second Quarter and Half-Year 2026 Results\n\nRegulated information(1)\n\nMaterialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed\nmedical devices and software, and a pioneer in additive manufacturing software\nand services, today announced its financial results for the second quarter and\nthe six months ended June 30, 2026.\n\nHighlights – Second Quarter 2026\n\n\n * Total revenue increased by 8.1% to 70,073 kEUR for the second quarter of 2026\ncompared to 64,831 kEUR for the corresponding 2025 period.\n\n * Adjusted EBITDA increased by 15.7% to 9,593 kEUR for the second quarter of\n2026 compared to 8,288 kEUR for the second quarter of 2025.\n\n * Adjusted EBIT increased by 26.9% to 3,880 kEUR for the second quarter of 2026\nfrom 3,058 kEUR for the second quarter of 2025.\n\n * Net profit for the second quarter of 2026 amounted to 3,331 kEUR, or 0.06 EUR\nper diluted share, compared to net profit of 199 kEUR, or 0.00 EUR per diluted\nshare, for the corresponding 2025 period.\n\n * The net cash position at quarter end was 74,214 kEUR, 1,388 kEUR higher\ncompared to the net cash position as of March 31, 2026 while 2,903 kEUR was\ninvested in share buybacks, underscoring continued strong operational cash\ngeneration.\n\nHighlights – Half-Year 2026\n\n\n * Driven by a strong 9.6% growth in our Materialise Medical segment, total\nrevenue increased by 3.9% to 136,349 kEUR for the first half of 2026 compared\nto 131,210 kEUR for the first half of 2025.\n\n * Gross profit as a percentage of revenue for the first half of 2026 was 57.0%,\ncompared to 56.8% for the first half of 2025.\n\n * Adjusted EBITDA increased by 22.2% to 17,642 kEUR for the first half of 2026\ncompared to 14,434 kEUR for the first half of 2025. Adjusted EBIT increased by\n71.4% to 6,351 kEUR for the first half of 2026 from 3,703 kEUR for the first\nhalf of 2025.\n\n * Net profit for the first half of 2026 amounted to 5,152 kEUR, or 0.09 EUR per\ndiluted share, compared to a net loss of (337) kEUR, or (0.01) EUR per diluted\nshare, for the first half of 2025.\n\n * Total cash reserves amounted to 133,735 kEUR at the end of the first half of\n2026. The net cash position increased by 3,409 kEUR during the first half of\n2026, while 5,212 kEUR was invested in share buybacks.\n\nCEO Brigitte de Vet-Veithen commented, “In the second quarter of 2026,\nMaterialise delivered strong financial results with consolidated revenue\nexceeding EUR 70 million, up 8% year over year. Double-digit revenue growth in\nour Materialise Medical segment was complemented by renewed growth in our\nManufacturing segment driven by strong performance in our aerospace &\ndefense focus markets. Combined with disciplined cost management and focused\nexecution, this revenue growth translated into a significant improvement in\noperational and bottomline profitability. Our net cash position further\nstrengthened supported by consistent operating cash flow while we continued\nthe execution of our share buyback program.\n\nWe also made meaningful progress against our strategic priorities during the\nquarter. Our Materialise Software segment launched its new CO-AM offerings, we\ncompleted the previously announced divestitures of our RapidFit and Eyewear\nbusiness lines, and we invested in Replasia to further expand our personalized\nhip care portfolio. These actions reflect our commitment to sharpening our\nfocus, strengthening our leadership in high-value applications, and building\nthe foundation for sustainable long-term growth. With a strong balance sheet,\nMaterialise is well positioned to capture further opportunities ahead and to\ncreate lasting value for customers, patients, partners, and shareholders.”\n __________________________ \n (1 )The enclosed information constitutes regulated information as defined in \n the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers \n of financial instruments which have been admitted for trading on a regulated \n market. \n\n\nSecond quarter 2026 Results\n\nTotal revenue for the second quarter of 2026 increased by 8.1% to 70,073 kEUR\nfrom 64,831 kEUR for the second quarter of 2025. Adjusted EBIT increased by\n26.9% to 3,880 kEUR for the second quarter of 2026 compared to 3,058 kEUR for\nthe 2025 period. The Adjusted EBIT margin (Adjusted EBIT divided by total\nrevenue) for the second quarter of 2026 was 5.5%, compared to 4.7% for the\nsecond quarter of 2025. Adjusted EBITDA for the second quarter of 2026\nincreased by 15.7% to 9,593 kEUR compared to 8,288 kEUR for the 2025 period.\n\nRevenue from our Materialise Medical segment increased 12.2% to 36,873 kEUR\nfor the second quarter of 2026 compared to 32,850 kEUR for the same period in\n2025. Segment Adjusted EBITDA increased 7.7% to 11,553 kEUR for the second\nquarter of 2026 compared to 10,728 kEUR, while the segment Adjusted EBITDA\nmargin was 31.3% compared to 32.7% for the second quarter of 2025.\n\nRevenue from our Materialise Software segment decreased 2.7% to 9,601 kEUR for\nthe second quarter of 2026 from 9,872 kEUR for the same quarter last year.\nSegment Adjusted EBITDA decreased to 981 kEUR from 1,373 kEUR, while the\nsegment Adjusted EBITDA margin was 10.2% compared to 13.9% for the prior-year\nperiod.\n\nRevenue from our Materialise Manufacturing segment increased 6.7% to 23,597\nkEUR for the second quarter of 2026 from 22,109 kEUR for the second quarter of\n2025. Segment Adjusted EBITDA improved to (285) kEUR compared to (807) kEUR\nfor the same period in 2025, while the segment Adjusted EBITDA margin was\n(1.2)% compared to (3.6)% for the second quarter of 2025.\n\nGross profit increased 5.3% to 39,776 kEUR for the second quarter of 2026\ncompared to 37,778 kEUR for the same period last year, while gross profit as a\npercentage of revenue ended at 56.8% compared to 58.3% for the second quarter\nof 2025.\n\nResearch and development (“R&D”), sales and marketing (“S&M”),\nand general and administrative (“G&A”) expenses increased, in the\naggregate, by 3.9% to 37,758 kEUR for the second quarter of 2026 from 36,334\nkEUR for the second quarter of 2025.\n\nNet other operating income was 766 kEUR compared to 1,286 kEUR for the second\nquarter of 2025. Net operating income in the second quarter of 2026 includes\nnon-recurring charges of 689 kEUR from the impairment of tangible and\nintangible assets related to the transfer of the Eyewear assets.\n\nOperating result remained fairly stable at 2,785 kEUR compared to 2,730 kEUR\nfor the second quarter of 2025, while net financial result was 242 kEUR,\ncompared to (3,052) kEUR for the second quarter of 2025. The latter being\nsignificantly impacted by unfavorable foreign exchange results.\n\nThe second quarter of 2026 contained net tax benefits of 304 kEUR, compared to\nnet tax benefits of 521 kEUR in the second quarter of 2025.\n\nAs a result of the above, net profit for the second quarter of 2026 increased\nsharply to 3,331 kEUR, compared to 199 kEUR for the same period in 2025.\n\nCash flow from operating activities for the second quarter of 2026 amounted to\n8,146 kEUR compared to (27) kEUR for the same period in 2025. Total cash used\nfor capital expenditures for the second quarter of 2026 amounted to 1,975 kEUR\nand free cash flow after operating and investing activities was 5,625 kEUR.\n\nHalf-Year 2026 Results\n\nTotal revenue for the first half of 2026 increased by 3.9% to 136,349 kEUR,\ncompared to 131,210 kEUR for the same period in 2025. Adjusted EBIT for the\nfirst half of 2026 increased by 71.4% to 6,351 kEUR, up from 3,703 kEUR for\nthe corresponding period in 2025. The Adjusted EBIT margin (Adjusted EBIT\ndivided by total revenue) for the first half of 2026 increased to 4.7%,\ncompared to 2.8% for the same period in 2025. Adjusted EBITDA for the first\nhalf of 2026 increased by 22.2% to 17,642 kEUR, compared to 14,434 kEUR for\nthe same period in 2025.\n\nRevenue from our Materialise Medical segment increased by 9.6% to 70,039 kEUR\nfor the first half of 2026, compared to 63,928 kEUR for the same period in\n2025. The segment’s Adjusted EBITDA increased by 5.1% to 20,787 kEUR from\n19,775 kEUR. The segment’s Adjusted EBITDA margin ended at 29.7% in the\nfirst half of 2026 compared to 30.9% for the first half of 2025.\n\nRevenue from our Materialise Software segment decreased 2.1% to 19,242 kEUR\nfor the first half of 2026 compared to 19,647 kEUR for the same period in\n2025. The segment’s Adjusted EBITDA increased by 6.7% to 2,103 kEUR from\n1,971 kEUR. The segment’s Adjusted EBITDA margin improved to 10.9% in the\nfirst half of 2026, compared to 10.0% in the first half of 2025.\n\nRevenue from our Materialise Manufacturing segment decreased 1.2% to 47,067\nkEUR for the first half of 2026 from 47,635 kEUR for the first half of 2025.\nThe segment’s Adjusted EBITDA improved to (4) kEUR compared to (1,185) kEUR.\nThe segment’s Adjusted EBITDA margin was (0.0)% in the first half of 2026,\ncompared to (2.5)% in the first half of 2025.\n\nConsolidated gross profit increased 4.3% to 77,670 kEUR from 74,502 kEUR in\nlast year’s first half. Gross profit as a percentage of revenue increased to\n57.0%, compared to 56.8% in the first half of 2025.\n\nResearch and development (“R&D”) expenses increased by 7.4% to 24,203\nkEUR in the first half of 2026 reflecting higher investments in our\nMaterialise Medical and Software segments. Other operational expenses,\nincluding sales and marketing (\"S&M\") and general and administrative\n(\"G&A\") expenses, remained stable in aggregate at 50,268 kEUR for the\nfirst half of 2026, compared to 50,311 kEUR for the first half of 2025.\n\nNet other operating income was 1,676 kEUR compared to 1,646 kEUR for the first\nhalf of 2025.\n\nOperating result increased to 4,875 kEUR for the first half of 2026 compared\nto 3,303 kEUR in the same period of the prior year.\n\nNet financial result amounted to 634 kEUR, compared to (3,927) kEUR for the\nfirst half of 2025.\n\nIncome taxes amounted to (358) kEUR compared to 287 kEUR for the first half of\n2025.\n\nAs a result, net profit amounted to 5,152 kEUR for the first half of 2026\ncompared to a net loss of (337) kEUR in the first half of 2025.\n\nCash flow from operating activities for the first half of 2026 increased to\n15,060 kEUR compared to 9,686 kEUR for the first half of 2025. Total capital\nexpenditures for the first half of 2026 amounted to 3,445 kEUR compared to\n6,561 kEUR for the first half of 2025. Free cash flow, after operating and\ninvesting activities, for the first half of 2026 amounted to 11,368 kEUR.\n\nAt June 30, 2026, we held cash and cash equivalents of 133,735 kEUR compared\nto 133,918 kEUR at December 31, 2025. Gross debt decreased to 59,521 kEUR,\ncompared to 63,113 kEUR at December 31, 2025. As a result, our net cash\nposition increased by 3,409 kEUR to 74,214 kEUR compared to 70,805 kEUR as of\nDecember 31, 2025. At the end of the second quarter of 2026 Materialise had\nbought back 1,070,797 own shares for a total amount (excluding transaction\ncost) of 5,212 kEUR (6,091 kUSD) under its previously announced share buy-back\nprogram.\n\nNet shareholders' equity at June 30, 2026 increased to 256,268 kEUR compared\nto 255,482 kEUR at December 31, 2025.\n\nOn August 27, 2026, Materialise released its 2026 Half-Year Report providing\nfurther insights in its operational and financial performance over the first\nhalf of 2026. This report is now also available on our Investor Relations\nwebsite under the reports\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.materialise.com%2Ffinancials%2Freports&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=reports&index=1&md5=5f2e54a86fb7a5c45b4d8ed3d96f25e9)\nsection. The timing of our second quarter financial results update was\nintentionally aligned with the public release of the 2026 Half-Year report.\n\n2026 Guidance\n\nMrs. de Vet-Veithen concluded,“Our solid first-half year performance\nreinforces our confidence in delivering on the financial targets we set for\n2026. The strategic actions we are taking to sharpen our portfolio and the\ntargeted investments we are making across our three segments are enhancing\noperational performance and positioning Materialise for profitable growth.\nAccordingly, we are reaffirming our full-year 2026 revenue guidance of 273,000\nto 283,000 kEUR, fully absorbing the unfavorable revenue impact of the\nRapidFit and Eyewear divestments. At the same time we are increasing our\nfull-year Adjusted EBIT guidance to a range of 12,000 to 14,000 kEUR from a\npreviously communicated range of 10,000 to 12,000 kEUR, reflecting the\nstrength of our execution and our continued discipline in managing costs and\ncapital.”\n\nNon-IFRS Measures\n\nMaterialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as\nsupplemental financial measures of its financial performance, including for\npurposes of monitoring compliance with financial covenants, supporting\ndiscussions with financing institutions, and meeting reporting requirements to\nour banks. EBIT is calculated as net profit plus income taxes, financial\nexpenses (less financial income) and shares of profit or loss in a joint\nventure. EBITDA is calculated as net profit plus income taxes, financial\nexpenses (less financial income), shares of profit or loss in a joint venture\nand depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are\ndetermined by adding to EBIT and EBITDA, respectively (i) share-based\ncompensation expenses, (ii) acquisition expenses related to business\ncombinations or divestiture-related expenses, (iii) impairments and\nrevaluation of fair value due to business combinations and (iv) costs incurred\nin relation to corporate initiatives, restructurings or reorganizations that\nare of a non-recurring nature. Management believes these non-IFRS measures to\nbe important measures as they exclude the effects of items which primarily\nreflect the impact of financing decisions and, in the case of EBITDA and\nAdjusted EBITDA, long term investment, rather than the performance of the\ncompany’s day-to-day operations. The company also uses segment Adjusted\nEBITDA and segment Adjusted EBITDA margin to evaluate the performance of its\nthree business segments. As compared to net profit, these measures are limited\nin that they do not reflect the cash requirements necessary to service\ninterest or principal payments on the company’s indebtedness and, in the\ncase of EBITDA and Adjusted EBITDA, these measures are further limited in that\nthey do not reflect the periodic costs of certain capitalized tangible and\nintangible assets used in generating revenues in the company’s business, or\nthe changes associated with impairments. Management evaluates such items\nthrough other financial measures such as financial expenses, capital\nexpenditures and cash flow provided by operating activities. The company\nbelieves that these measurements are useful to measure a company’s ability\nto grow or as a valuation measurement. The company’s calculation of EBIT,\nEBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly\ntitled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and\nAdjusted EBITDA should not be considered as alternatives to net profit or any\nother performance measure derived in accordance with IFRS. The company’s\npresentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be\nconstrued to imply that its future results will be unaffected by unusual or\nnon-recurring items.\n\nExchange Rate\n\nThis document contains translations of certain euro amounts into U.S. dollars\nat specified rates solely for the convenience of readers. Unless otherwise\nnoted, all translations from euros to U.S. dollars in this document were made\nat a rate of EUR 1.00 to USD 1.1394, the reference rate of the European\nCentral Bank on June 30, 2026.\n\nConference Call and Webcast\n\nMaterialise will hold a conference call and simultaneous webcast to discuss\nits second quarter and half-year financial results of 2026 on Thursday, August\n27, 2026, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will\ninclude Brigitte de Vet-Veithen, Chief Executive Officer and Koen Berges,\nChief Financial Officer. A question-and-answer session will follow\nmanagement’s remarks.\n\nTo access the call by phone, please click the link below at least 15 minutes\nprior to the scheduled start time and you will be provided with dial-in\ndetails. Participants can choose to dial in or receive a call to connect to\nMaterialise’s conference call.\n\n\n * https://register-conf.media-server.com/register/BI1b662511962140febfa1a767c86a06ee\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI1b662511962140febfa1a767c86a06ee&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI1b662511962140febfa1a767c86a06ee&index=2&md5=114a38bf5b1cbea16acac6085c09eefc)\n\nThe conference call will also be broadcast live over the Internet with an\naccompanying slide presentation, which can be accessed on the company’s\nwebsite at http://investors.materialise.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestors.materialise.com&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=http%3A%2F%2Finvestors.materialise.com&index=3&md5=d7583eab6c255bb3ea65d2bb3af1c9c9)\n. The webcast of the conference call will be archived on the company's website\nfor one year.\n\nAbout Materialise\n\nMaterialise NV incorporates more than three decades of 3D printing experience\ninto a range of software solutions and 3D printing services that empower\nsustainable 3D printing applications. Our open, secure, and innovative\nend-to-end solutions enable flexible industrial manufacturing and mass\npersonalization in various industries — including healthcare, automotive,\naerospace, art and design, wearables, and consumer goods. Headquartered in\nBelgium and with branches worldwide, Materialise NV combines the largest group\nof software developers in the industry with one of the world's largest and\nmost complete 3D printing facilities. For additional information, please\nvisit: www.materialise.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.materialise.com&esheet=54595168&newsitemid=20260826250614&lan=en-US&anchor=www.materialise.com&index=4&md5=e5ffee95159e11086b6d6f3317bd5c8c)\n.\n\nCautionary Statement on Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, regarding, among other things,\nour intentions, beliefs, assumptions, projections, outlook, analyses or\ncurrent expectations, plans, objectives, strategies and prospects, both\nfinancial and business, including statements concerning, among other things,\nour estimates for the current fiscal year’s revenue and Adjusted EBIT, our\nresults of operations, cash needs, capital expenditures, expenses, financial\ncondition, liquidity, prospects, divestitures, growth and strategies\n(including how our business, results of operations and financial condition\ncould be impacted by the current armed geopolitical conflicts around the world\nand governmental responses thereto, inflation, increased labor, energy and\nmaterials costs), policy changes resulting from the U.S. presidential\nadministration, changes in tariffs and trade restrictions, and the trends and\ncompetition that may affect the markets, industry or us. Such statements are\nsubject to known and unknown uncertainties and risks. When used in this press\nrelease, the words “estimate,” “expect,” “anticipate,”\n“project,” “plan,” “intend,” “believe,” “forecast,”\n“will,” “may,” “could,” “might,” “aim,” “should,” and\nvariations of such words or similar expressions are intended to identify\nforward-looking statements. These forward-looking statements are based upon\nthe expectations of management under current assumptions at the time of this\npress release. These expectations, beliefs and projections are expressed in\ngood faith and the company believes there is a reasonable basis for them.\nHowever, the company cannot offer any assurance that our expectations, beliefs\nand projections will actually be achieved. By their nature, forward-looking\nstatements involve risks and uncertainties because they relate to events,\ncompetitive dynamics and industry change, and depend on economic circumstances\nthat may or may not occur in the future or may occur on longer or shorter\ntimelines than anticipated. We caution you that forward-looking statements are\nnot guarantees of future performance and involve known and unknown risks,\nuncertainties and other factors that are in some cases beyond our control. All\nof the forward-looking statements are subject to risks and uncertainties that\nmay cause the company's actual results to differ materially from our\nexpectations, including risk factors described in the company's most recent\nannual report on Form 20-F filed with the U.S. Securities and Exchange\nCommission. There are a number of risks and uncertainties that could cause the\ncompany's actual results to differ materially from the forward-looking\nstatements contained in this press release.\n\nThe company is providing this information as of the date of this press release\nand does not undertake any obligation to update any forward-looking statements\ncontained in this press release as a result of new information, future events\nor otherwise, unless it has obligations under the federal securities laws to\nupdate and disclose material developments related to previously disclosed\ninformation.\n Consolidated income statements (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In '000 2026   2026   2025   2026   2025   \n U.S.$ € € € € \n Revenue 79,841   70,073   64,831   136,349   131,210   \n Cost of Sales (34,520 ) (30,297 ) (27,053 ) (58,679 ) (56,708 ) \n Gross Profit 45,321   39,776   37,778   77,670   74,502   \n Gross profit as % of revenue 56.8 % 56.8 % 58.3 % 57.0 % 56.8 % \n   \n Research and development expenses (14,029 ) (12,312 ) (11,120 ) (24,203 ) (22,534 ) \n Sales and marketing expenses (17,329 ) (15,209 ) (15,471 ) (30,644 ) (30,542 ) \n General and administrative expenses (11,663 ) (10,236 ) (9,744 ) (19,623 ) (19,769 ) \n Net other operating income/(expense) 873   766   1,286   1,676   1,646   \n Operating profit (loss) 3,173   2,785   2,730   4,875   3,303   \n   \n Financial expenses (993 ) (871 ) (4,039 ) (1,571 ) (6,811 ) \n Financial income 1,268   1,113   987   2,205   2,884   \n Profit (loss) before taxes 3,448   3,027   (322 ) 5,510   (624 ) \n   \n Income tax benefit/(expense) 347   304   521   (358 ) 287   \n Net profit (loss) for the period 3,795   3,331   199   5,152   (337 ) \n Net profit (loss) attributable to: \n The owners of the parent 3,795   3,331   199   5,152   (336 ) \n Non-controlling interest -   0   -   0   (2 ) \n   \n Earning per share attributable to owners of the parent \n Basic 0.07   0.06   0.00   0.09   (0.01 ) \n Diluted 0.07   0.06   0.00   0.09   (0.01 ) \n   \n Weighted average basic shares outstanding 58,310   58,310   59,067   58,586   59,067   \n Weighted average diluted shares outstanding 58,329   58,329   59,067   58,592   59,067   \n\n Consolidated statements of comprehensive income (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2026   2025 2026   2025   \n U.S.$ € € € € \n Net profit (loss) for the period 3,795   3,331   199 5,152   (337 ) \n Other comprehensive income/(loss) \n Items that are or may be reclassified subsequently to profit or loss \n Exchange difference on translation of foreign operations 91   80   624 257   1,129   \n Exchange differences resulting from net investment in foreign operations 182   160   - 537   -   \n Other comprehensive income/(loss), net of taxes 273   240   624 794   1,129   \n Total comprehensive income/(loss), net of taxes 4,069   3,571   823 5,946   792   \n Total comprehensive income/(loss) attributable to: \n The owners of the parent 4,071   3,573   817 5,951   785   \n Non-controlling interests (2 ) (2 ) 6 (5 ) 7   \n\n Consolidated statement of financial position (Unaudited) \n   \n As of As of \n June 30, December 31, \n In 000€ 2026 2025 \n Assets \n Non-current assets \n Goodwill 43,205 43,161 \n Intangible assets 23,281 25,639 \n Property, plant & equipment 109,776 112,854 \n Right-of-Use assets 5,873 5,429 \n Deferred tax assets 4,158 3,971 \n Investments in convertible loans 404 - \n Investments in non-listed equity instruments 8 - \n Other non-current assets 9,739 5,983 \n Total non-current assets 196,443 197,038 \n Current assets \n Inventories 16,846 14,904 \n Trade receivables 56,173 54,938 \n Other current assets 14,468 15,533 \n Cash and cash equivalents 133,735 133,918 \n Assets held for sale 0 4,314 \n Total current assets 221,221 223,607 \n Total assets 417,665 420,646 \n\n As of As of \n June 30, December 31, \n In 000€ 2026   2025   \n Equity and liabilities \n Equity \n Share capital 4,487   4,487   \n Share premium 203,895   203,895   \n Treasury shares (5,230 ) -   \n Retained earnings and other reserves 53,202   47,180   \n Equity attributable to the owners of the parent 256,354   255,562   \n Non-controlling interest (86 ) (80 ) \n Total equity 256,268   255,482   \n Non-current liabilities \n Loans & borrowings 46,745   49,726   \n Lease liabilities 3,526   3,063   \n Deferred tax liabilities 2,467   2,660   \n Deferred income 16,286   17,344   \n Other non-current liabilities 417   486   \n Total non-current liabilities 69,441   73,280   \n Current liabilities \n Loans & borrowings 6,775   7,759   \n Lease liabilities 2,475   2,565   \n Trade payables 19,382   20,125   \n Tax payables 934   748   \n Deferred income 46,267   43,523   \n Other current liabilities 16,122   16,362   \n Liabilities held for sale 0   802   \n Total current liabilities 91,955   91,884   \n Total equity and liabilities 417,665   420,646   \n\n Consolidated statement of cash flows (Unaudited) \n   \n for the six months ended \n June 30, \n In 000€ 2026   2025   \n Operating activities \n Net (loss) profit for the period 5,152   (337 ) \n Non-cash and operational adjustments \n Depreciation of property plant & equipment 8,097   7,448   \n Amortization of intangible assets 3,965   3,210   \n Share-based payment expense 115   117   \n Loss (gain) on disposal of intangible assets and property, plant & equipment (331 ) (21 ) \n Government grants (239 ) (101 ) \n Movement in provisions (49 ) (366 ) \n Movement reserve for bad debt and slow moving inventory 449   271   \n Financial income (2,225 ) (2,876 ) \n Financial expense 1,598   6,770   \n Impact of foreign currencies (59 ) (70 ) \n Income taxes and deferred taxes 359   (295 ) \n Working capital adjustments and income tax (paid)/received \n Decrease (increase) in trade receivables and other receivables (210 ) 2,093   \n Decrease (increase) in inventories and contracts in progress (2,246 ) (500 ) \n Increase in trade payables and other payables (807 ) (6,278 ) \n Income tax (paid)/received 184   (679 ) \n Interest received 1,308   1,300   \n Net cash flow from operating activities 15,060   9,686   \n\n for the six months ended \n June 30, \n In 000€ 2026   2025   \n Investing activities \n Purchase of property, plant & equipment (2,792 ) (5,617 ) \n Purchase of intangible assets (654 ) (944 ) \n Proceeds from the sale of property, plant & equipment & intangible assets 409   233   \n Cash transferred out upon divestment (488 ) -   \n Investments in associates and joint ventures (8 ) -   \n Convertible loan to third party (400 ) -   \n Capital government grants received 240   2,640   \n Net cash flow used in investing activities (3,692 ) (3,688 ) \n Financing activities \n Proceeds from loans & borrowings -   20,000   \n Repayment of loans & borrowings (3,951 ) (6,860 ) \n Repayment of leases (1,917 ) (1,544 ) \n Interest paid (978 ) (621 ) \n Other financial income (expense), net 18   (1,300 ) \n Repurchase of treasury shares (5,230 ) -   \n Net cash flow from (used in) financing activities (12,058 ) 9,676   \n Net increase/(decrease) of cash & cash equivalents (690 ) 15,673   \n Cash & Cash equivalents at the beginning of the year 133,918   102,304   \n Exchange rate differences on cash & cash equivalents 507   (913 ) \n Cash & cash equivalents at end of the period 133,735   117,064   \n\n Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n Depreciation and amortization 5,712   5,230   11,291   10,731   \n EBITDA 8,497   7,960   16,167   14,034   \n Share-based compensation expense (1) 59   45   115   117   \n Restructuring and corporate initiatives (2) 178   283   435   283   \n Impairments (3) 689   -   756   -   \n Divestitures-related expenses (4) 169   -   169   -   \n Adjusted EBITDA 9,593   8,288   17,642   14,434   \n\n (1) Share-based compensation expense represents the cost of equity-settled and \n share-based payments to employees. \n (2) Non-recurring costs related to corporate initiatives, restructurings or \n reorganizations. \n (3) Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (4) Divestitures-related expenses represent fees and costs in connection with the \n divestitures of RapidFit and Eyewear. \n\n Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n EBIT 2,785   2,730   4,876   3,303   \n Share-based compensation expense (1) 59   45   115   117   \n Restructuring and corporate initiatives (2) 178   283   435   283   \n Impairments (3) 689   -   756   -   \n Divestitures-related expenses (4) 169   -   169   -   \n Adjusted EBIT 3,880   3,058   6,351   3,703   \n\n (1)   Share-based compensation expense represents the cost of equity-settled and \n share-based payments to employees. \n (2)   Non-recurring costs related to corporate initiatives, restructurings or \n reorganizations. \n (3)   Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (4)   Divestitures-related expenses represent fees and costs in connection with the \n divestitures of RapidFit and Eyewear. \n\n Segment P&L (Unaudited) \n   \n In 000€ Materialise Materialise Materialise Total Unallocated (1) Consolidated \n Medical Software Manufacturing segments \n For the three months ended June 30, 2026 \n Revenues 36,873   9,601   23,597   70,071   2   70,073   \n Segment (adj) EBITDA 11,553   981   (285 ) 12,248   (2,656 ) 9,593   \n Segment (adj) EBITDA % 31.3 % 10.2 % -1.2 % 17.5 % 13.7 % \n For the three months ended June 30, 2025 \n Revenues 32,850   9,872   22,109   64,831   (0 ) 64,831   \n Segment (adj) EBITDA 10,728   1,373   (807 ) 11,294   (3,005 ) 8,288   \n Segment (adj) EBITDA % 32.7 % 13.9 % -3.6 % 17.4 % 12.8 % \n   \n In 000€ Materialise Materialise Materialise Total Unallocated (1) Consolidated \n Medical Software Manufacturing segments \n For the six months ended June 30, 2026 \n Revenues 70,039   19,242   47,067   136,347   2   136,349   \n Segment (adj) EBITDA 20,787   2,103   (4 ) 22,886   (5,245 ) 17,642   \n Segment (adj) EBITDA % 29.7 % 10.9 % 0.0 % 16.8 % 12.9 % \n For the six months ended June 30, 2025 \n Revenues 63,928   19,647   47,635   131,210   (0 ) 131,210   \n Segment (adj) EBITDA 19,775   1,971   (1,185 ) 20,561   (6,127 ) 14,434   \n Segment (adj) EBITDA % 30.9 % 10.0 % -2.5 % 15.7 % 11.0 % \n\n (1)    Unallocated segment adjusted EBITDA consists of corporate research and \n development and corporate other operating income (expense), and the added \n share-based compensation expenses, acquisition expenses related to business \n combinations or divestiture-related expenses, impairments and revaluation of \n fair value of business combinations and non-recurring costs related to \n corporate initiatives, restructurings and reorganizations that are included in \n Adjusted EBITDA and that are not allocated to the reporting segments . \n\n Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited) \n   \n for the three months ended for the six months ended \n June 30, June 30, \n In 000€ 2026   2025   2026   2025   \n Net profit (loss) for the period 3,331   199   5,152   (337 ) \n Income taxes (304 ) (521 ) 358   (287 ) \n Financial expenses 871   4,039   1,571   6,811   \n Financial income (1,113 ) (987 ) (2,205 ) (2,884 ) \n Operating (loss) profit 2,785   2,730   4,876   3,303   \n Depreciation and amortization 5,712   5,230   11,291   10,731   \n Corporate research and development 935   1,070   1,813   2,100   \n Corporate headquarter costs 3,219   2,895   6,215   5,747   \n Other operating income (expense) (1,151 ) (810 ) (2,125 ) (1,498 ) \n Impairments (1) 689   -   756   -   \n Segment restructuring and reorganization (2) 59   178   59   178   \n Segment adjusted EBITDA 12,248   11,294   22,886   20,561   \n\n (1)    Impairments represent the impairment of tangible and intangible assets of \n RapidFit NV and Eyewear resulting from the transfer of the assets to their \n respective management teams. \n (2)    Costs related to restructuring activities and organizational changes within \n specific reported business segments, including personnel‑related and other \n associated expenses. \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260826250614/en/\n(https://www.businesswire.com/news/home/20260826250614/en/)\n\nInvestor Relations Contact\n\nJody Burfening\n\nAlliance Advisors Investor Relations\n\n+1-212-838-3777\n\nMaterialiseIR@allianceadvisors.com (mailto:MaterialiseIR@allianceadvisors.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-27T05:00:00.227848901Z","server_sent_at_ms":1787806800227},"received_at":"2026-08-27T05:00:00.441Z","source_url":"https://www.businesswire.com/news/home/20260826250614/en/"},"analysis":{"id":"117687","press_release_id":"128770","analysis_json":{"industry":{"label":"Technology Hardware, Storage & Peripherals","sector":"Information Technology"},"redFlags":[],"eventType":"earnings","narrative":"Materialise reported Q2 2026 revenue of €70.1 million, up 8.1% year-over-year, driven by double-digit growth in its Medical segment and a return to growth in Manufacturing.\n\nProfitability improved significantly, with Adjusted EBIT rising 26.9% to €3.9 million and net profit reaching €3.3 million compared to just €0.2 million in the prior-year period.\n\nThe company raised its full-year 2026 Adjusted EBIT guidance to €12-14 million from €10-12 million while reaffirming revenue targets, and invested €5.2 million in share buybacks during the first half.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Profitability surge and guidance raise highlight successful execution despite divestiture impact."},"keyFigures":{"eps":0.06,"revenue":70073000,"guidance":"FY26 revenue €273,000-€283,000 kEUR; Adjusted EBIT raised to €12,000-€14,000 kEUR from €10,000-€12,000 kEUR","revenueYoy":"8.1%","customDimensions":{"ebit_adj":3880000,"net_cash":74214000,"ebitda_adj":9593000,"net_profit":3331000,"buyback_h1_2026":5212000}},"quotedText":"In the second quarter of 2026, Materialise delivered strong financial results with consolidated revenue exceeding EUR 70 million, up 8% year over year.","namedEntities":{"people":[{"name":"Brigitte de Vet-Veithen","role":"CEO"},{"name":"Koen Berges","role":"CFO"}],"products":["CO-AM","RapidFit","Eyewear"],"companies":[{"name":"Materialise NV","ticker":"MTLS"}],"dollarAmounts":[{"amount":"70,073 kEUR","context":"Q2 2026 total revenue"},{"amount":"3,331 kEUR","context":"Q2 2026 net profit"},{"amount":"5,212 kEUR","context":"H1 2026 share buyback investment"},{"amount":"74,214 kEUR","context":"Q2 2026 net cash position"}]},"materialImpact":{"score":4,"reasoning":"Solid 8.1% revenue growth in Q2 accompanied by a 26.9% increase in Adjusted EBIT and a significant swing to profitability. Management raised full-year Adjusted EBIT guidance by approximately 20% while maintaining revenue outlook despite divestiture headwinds."},"tickerRelevance":{"others":[],"primary":"MTLS"},"globalImportance":20,"audienceRelevance":20,"eventTypeSecondary":["guidance_update","buyback"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"earnings-with-guidance-raise","sectorWeight":"tech-3d-printing"}},"event_type":"earnings","event_type_secondary":["guidance_update","buyback"],"sentiment":"bullish","material_impact_score":4,"narrative":"Materialise reported Q2 2026 revenue of €70.1 million, up 8.1% year-over-year, driven by double-digit growth in its Medical segment and a return to growth in Manufacturing.\n\nProfitability improved significantly, with Adjusted EBIT rising 26.9% to €3.9 million and net profit reaching €3.3 million compared to just €0.2 million in the prior-year period.\n\nThe company raised its full-year 2026 Adjusted EBIT guidance to €12-14 million from €10-12 million while reaffirming revenue targets, and invested €5.2 million in share buybacks during the first half.","key_figures":{"eps":0.06,"revenue":70073000,"guidance":"FY26 revenue €273,000-€283,000 kEUR; Adjusted EBIT raised to €12,000-€14,000 kEUR from €10,000-€12,000 kEUR","revenueYoy":"8.1%","customDimensions":{"ebit_adj":3880000,"net_cash":74214000,"ebitda_adj":9593000,"net_profit":3331000,"buyback_h1_2026":5212000}},"named_entities":{"people":[{"name":"Brigitte de Vet-Veithen","role":"CEO"},{"name":"Koen Berges","role":"CFO"}],"products":["CO-AM","RapidFit","Eyewear"],"companies":[{"name":"Materialise NV","ticker":"MTLS"}],"dollarAmounts":[{"amount":"70,073 kEUR","context":"Q2 2026 total revenue"},{"amount":"3,331 kEUR","context":"Q2 2026 net profit"},{"amount":"5,212 kEUR","context":"H1 2026 share buyback investment"},{"amount":"74,214 kEUR","context":"Q2 2026 net cash position"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T05:02:44.713Z","global_importance":20,"audience_relevance":20,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"earnings-with-guidance-raise","sectorWeight":"tech-3d-printing"}},"durationMs":164253,"modelName":"glm-4.7"}}